Brief history
=============

Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. In the United States, rates range from 5% to 6% of school-age children ([@b18-ndt-2-467]; [@b24-ndt-2-467]).The illness is characterized by a triad of symptom clusters which include inattention, hyperactivity, and impulsivity. Usually the illness is first detected during the early school years ([@b15-ndt-2-467]), but can persist during adolescence and even adulthood. If left untreated, ADHD can be associated with a number of poor outcomes including academic failure, delinquency, and problems with substance abuse ([@b3-ndt-2-467]; [@b4-ndt-2-467]; [@b10-ndt-2-467]; [@b61-ndt-2-467]).

Stimulants have been the mainstay of pharmacological treatment of ADHD for over 60 years. Their effect on disruptive behavior was discovered in 1937, when these drugs proved to increase compliance, improve academic performance, and reduce motor activity in hyperactive children ([@b5-ndt-2-467]). Methylphenidate (MPH) is the most frequently prescribed among stimulant agents. It has proven efficacy on ADHD symptoms ([@b22-ndt-2-467]; [@b16-ndt-2-467]).

*d*-MPH vs *d,l*-MPH (racemic MPH)
==================================

Until the introduction of the *d-*MPH (*d-threo-*(*R,R*)*-*MPH, *d-*MPH) in 2002, all clinically used MPH formulations contained a racemic (1:1) mixture of *d-threo-*(*R,R*)*-*MPH and *l-threo-*(*R,R*)*-*MPH isomers ([Figure 1](#f1-ndt-2-467){ref-type="fig"}). The development of *d-*MPH was based on the findings that similar improvement on sustained attention was achieved after treatment with *d*-equivalent doses of *d*-MPH and *d,l*-MPH, but not after *l*-MPH ([@b41-ndt-2-467]). It was found that clinical efficacy was highly correlated with plasma concentrations of *d*-MPH. The elimination of the *l*-isomer does not diminish the efficacy of an acute dose of MPH ([@b36-ndt-2-467]). The efficacy of the *d-*isomer was equivalent to the racemic preparation in ameliorating the target symptoms of ADHD and increasing academic productivity. Thus, it was thought that the efficacy of MPH resides in the *d*-isomer ([@b25-ndt-2-467]; [@b31-ndt-2-467]; [@b42-ndt-2-467], [@b41-ndt-2-467]). Other research demonstrated that besides clinical effectiveness, the undesired pressor and anorexic actions of *d,l*-MPH also appear to reside in the *d-*isomer ([@b41-ndt-2-467]; [@b1-ndt-2-467]; [@b37-ndt-2-467]; [@b48-ndt-2-467]).

*d*-MPH not only appears to be the more active of the two enantiomers, but also better absorbed; plasma concentrations of *d*-MPH are many times higher than the *l*-enantiomer after oral dosing of racemic MPH ([@b19-ndt-2-467]; [@b7-ndt-2-467]; [@b22-ndt-2-467]; [@b30-ndt-2-467]) or intravenous administration ([@b22-ndt-2-467]). This is seen with both immediate-release ([@b22-ndt-2-467]) and sustained-released ([@b19-ndt-2-467]; [@b22-ndt-2-467]) forms of racemic MPH. The pre-systemic metabolism and metabolic clearance of *d,l*-MPH is also an enantioselective process which, too, contributes to markedly higher plasma concentrations of *d-*MPH relative to *l-*MPH ([@b28-ndt-2-467]; [@b32-ndt-2-467]). It was also found that equimolar doses of *d-*MPH yielded similar pharmacokinetics as those noted with administration of the *d,l*-racemic mixture ([@b41-ndt-2-467]).

As a result, the *d*-MPH product was developed, and approved by the FDA for clinical use on August 31 2001. The *d*-MPH product appears to double the therapeutic potency of the racemic *d,l*-MPH; when only half dose of racemic *d,l*-MPH was used, *d*-MPH produced similar pharmacokinetic parameters (C~max~, T~max~, and half-life) ([@b1-ndt-2-467]; [@b20-ndt-2-467]; [@b28-ndt-2-467]). The administration of *d*-MPH with food has no significant effect on bioavailability, but with racemic MPH, T~max~ was delayed by 1 hour ([@b48-ndt-2-467]). In addition, a number of studies ([@b33-ndt-2-467]; [@b2-ndt-2-467]; [@b36-ndt-2-467]; [@b38-ndt-2-467]; [@b60-ndt-2-467]) suggested that *d*-MPH might have a longer duration of action than *d,l*-MPH on tests measuring attention, hyperactivity, and impulsivity. However, this requires further controlled study. As mentioned before, the use of *d-*MPH in ADHD allows the administration of lower doses than those currently prescribed with *d,l*-MPH.

Chemistry
=========

Molecules that are non-superimposable mirror images of one another are termed enantiomers and when equal amounts (1:1) of enantiomeric molecules are present together, the product is termed racemic. Most current commercial formulations of MPH consist of the racemic mixture of the *threo* pair of MPH isomers (*d,l-threo* MPH).

Although MPH has two chiral centers, and therefore four isomers, a *d,l-erythro*-MPH pair and a *d,l-threo*-MPH pair, only the racemic mixture of the *threo* pair of enantiomers (*d,l-threo*-MPH) is used therapeutically. This is due to the recognition that it has fewer side-effects than the *erythro* enantiomers. [Figure 1](#f1-ndt-2-467){ref-type="fig"} shows the chemical structures of *d-* and *l-threo*-MPH. It should be noted that the phenethylamine moiety of *d-*MPH is shared by dopamine and norepinephrine. It is the phenethylamine structure that provides the transporter receptor affinity and it competes with dopamine for binding ([@b22-ndt-2-467]).

The predominant metabolic pathway of MPH is de-esterification to form pharmacologically inactive *d-* or *l-*ritalinice acid by the carboxyesterase-I isoform, CES1A1 ([@b44-ndt-2-467]). It was shown that *d,l-threo*-methylphenidate was stereoselectively metabolized in humans ([@b25-ndt-2-467]; [@b42-ndt-2-467]), with *l-threo*-MPH being eliminated faster than *d-threo*-MPH ([@b41-ndt-2-467]; [@b44-ndt-2-467]). In a double-blind, four-way, randomized, crossover study, *l*-MPH showed no difference vs placebo in improving the sustained attention in humans. Moreover, a 5-mg dose of *d*-*threo*-MPH has the same attention improvement effect as a 10-mg dose of *d,l*-*threo*-MPH racemic mixture. Hence, the clinical effect of MPH is attributed to the *d*-enantiomer ([@b41-ndt-2-467]). The brand name for *d-*MPH is Focalin^®^. In terms of its chemical composition, *d-*MPH hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, (R,R′)-(+)-. Its empirical formula is C~14~H~19~NO~2~·HCl. Its molecular weight is 269.77.

Binding and imaging studies of *d-*isomer vs *l-*isomer: from animals to humans
===============================================================================

Although its mechanism is poorly understood, pharmacodynamic studies have suggested that the therapeutic effect of MPH in the treatment of ADHD appears to lie primarily in increasing the synaptic concentration of dopamine by blocking dopamine transporters (DAT) ([@b13-ndt-2-467]; [@b7-ndt-2-467]; [@b6-ndt-2-467]), as well as in blocking norepinephrine transporters. This is in agreement with recent reports that there is significantly increased expression of DAT in ADHD patients ([@b57-ndt-2-467]) and the effects of MPH administration is associated with a decrease in DAT receptor concentration in the striatum ([@b23-ndt-2-467]).

Normally, DAT decreases with age ([@b55-ndt-2-467]). However, in methamphetamine abusers, the number of DAT also are reduced ([@b53-ndt-2-467], [@b54-ndt-2-467]). Recovery of DAT receptors is evident with protracted abstinence ([@b53-ndt-2-467]). The binding of *d*-MPH to DAT in the striatum is reduced by cocaine in a dose-dependent manner ([@b11-ndt-2-467]).

Studies in humans, baboons, and rats seem to indicate that the pharmacological specificity of MPH resides predominantly in its *d*-isomer ([@b41-ndt-2-467]; [@b7-ndt-2-467]; [@b1-ndt-2-467]). Thus, in vivo binding measures of radiolabeled *d-*MPH to dopamine transporter in the brain with positron emission tomography (PET) or microdialysis have not only become a valuable technique to analyze pharmacodynamics of MPH and its enantiomers ([@b8-ndt-2-467], [@b7-ndt-2-467], [@b9-ndt-2-467]; [@b12-ndt-2-467]; [@b27-ndt-2-467], 2001; [@b57-ndt-2-467]; [@b21-ndt-2-467]), but also served as an effective tool to assess expression or density of dopamine transporters in tissues of humans and animals ([@b56-ndt-2-467], [@b55-ndt-2-467], [@b53-ndt-2-467], [@b54-ndt-2-467]; [@b11-ndt-2-467]; [@b14-ndt-2-467]).

PET studies provide a quantitative measure of distribution volume ratios, which represent specific radioligand binding ([@b56-ndt-2-467]; [@b58-ndt-2-467]). Measures of distribution volume ratios are based upon the following assumptions: (i) Even if the plasma concentration of the radiolabeled tracer is unknown (for example, without blood samples from patients), "non-invasive" quantification is still possible using a reference region with graphical analysis ([@b27-ndt-2-467]); (ii) for neuroreceptor--transporter modeling, no specific binding occurs in the reference region ([@b57-ndt-2-467]); (iii) the distribution volume of the reference region is the same as the distribution volume of the first compartment (free and non-specifically bound tracer) in the target region. Since the basal ganglia of striatum expresses more dopamine transporters (DAT), it is considered as the target region for *d-*MPH, while the cerebellum does not express DAT, so it usually is considered the reference region ([@b57-ndt-2-467]; [@b21-ndt-2-467]). Thus, the tissue distribution volume ratio of \[^11^C\]*d*-MPH in the basal ganglia containing the specific binding to that in the cerebellum which demonstrates non-specific binding should be considered to be a reflection of dopamine transporter availability.

Recent results from PET and other imaging studies for the two enantiomers of racemic MPH demonstrated that \[^11^C\]*d*-MPH bound to the dopamine transporter in the basal ganglia is highly specific and reproducible ([@b7-ndt-2-467]). However, there is no evidence of regional specific binding for \[^11^C\]*l-threo*-MPH in the brain. These results suggest that the binding of MPH to DAT in the striatum is enantiospecific. These data are also in agreement with those from basic and clinical studies showing that *d*-MPH at therapeutic doses exerts much stronger effects than racemic MPH or *l-threo*-MPH on extracellular dopamine in rats and on improvement in sustained attention in children ([@b41-ndt-2-467]; [@b31-ndt-2-467]).

Moreover, *d*- and *l*-MPH also undergo enantioselective metabolism ([@b42-ndt-2-467]; [@b19-ndt-2-467]; [@b1-ndt-2-467]; [@b44-ndt-2-467]), as evidenced by the following findings. First, as mentioned before, because of rapid pre-systemic metabolism, orally administered *l-threo*-MPH is poorly absorbed in humans. Thus, the absolute bioavailability of *d*-MPH is significantly greater than that of *l-threo*-MPH ([@b43-ndt-2-467]; [@b44-ndt-2-467]). Second, because there is a correlation between plasma concentrations and DAT occupancy, the plasma concentration could serve as an indicator for DAT binding ([@b41-ndt-2-467]). However, DAT binding by *d*-MPH could also be obtained from calculated tissue distribution volume without patients' blood samples ([@b27-ndt-2-467]). Third, while the rate of brain uptake for both enantiomers was not significantly different, the rate of clearance after 1.5 hours from the brain or plasma was much slower for *d*-MPH than that of *l-threo*-MPH ([@b57-ndt-2-467]). Fourth, greater than 50% DAT binding in the basal ganglia by *d-*MPH may be required for therapeutic efficacy for ADHD. However, despite greater than 50% DAT occupancy by *d*-MPH when administered intravenously or orally, the reinforcing effects were not perceived by patients receiving oral *d*-MPH ([@b57-ndt-2-467]). This phenomenon is possibly due to slower blockade of DAT by oral *d*-MPH and may explain why intravenous injection of MPH may lead to addiction. Finally, there is no inter-conversion between the enantiomers after oral administration of pure *d-* and *l*-MPH separately ([@b57-ndt-2-467]).

The recent in vitro binding study of [@b29-ndt-2-467] found that *d*-MPH exhibited prominent effects at the norepinephrine transporter site, even exceeding the activity at the DAT. The result demonstrated that affinity for catecholaminergic sites largely resides in the *d*-isomer.

Toxicology studies in animals
=============================

Animal toxicology studies showed that the toxicity of *d*-MPH and *d,l*-MPH were comparable at equimolar doses ([@b46-ndt-2-467]). A recent comparative study assessing the acute behavioral toxicity of *d*-MPH, *l*-MPH, and *d,l*-MPH in rats has revealed that females were more sensitive than males to some toxic behavioral effects of the *l-*isomer and *d,l-*MPH (racemic), suggesting a possible sex difference in sensitivity ([@b52-ndt-2-467]). In related studies, increased incidence of dilated pupils and vocalization was found with *d,l-*MPH compared with the pure *d*-MPH given at half the dose ([@b46-ndt-2-467]). In the same study, no other significant toxic effects were found in perinatal or postnatal rats at a dose 25 times the maximum daily human therapeutic dose ([@b46-ndt-2-467]). Another toxicology study in beagle dogs demonstrated that only minimal reversible toxicity such as reduced appetite and weight loss were found in male and female dogs receiving 10 mg/kg of *d*-MPH and 20 mg/kg of *d,l*-MPH for 90 days ([@b50-ndt-2-467]).

Neither *d*-MPH nor *d,l-*MPH were found to be carcinogenic or clastogenic in either in vitro or in vivo studies, although very high oral doses of the *l*-MPH produce behavioral, and even lethal, effects in mice ([@b47-ndt-2-467]). The authors believed that *d*-MPH and *d,l-*MPH do not present carcinogenic risk to humans. Animal studies in rats and rabbits also suggested that *d*-MPH and *d,l*-MPH were not teratogenic ([@b49-ndt-2-467]). The same study suggested that some negative behaviors in pregnant animals may be attributed to *l*-MPH because inclusion of the *l*-isomer, when comparing *d,l*-MPH and *d-*MPH at half the dose, resulted in repetitive pawing, dilated pupil, and aggressive behavior. A recent study, using PET and MicroPET to trace orally administered, as well as radiola-beled *d*- and *l*-MPH, in the brain of baboons and rats, suggested that *l*-MPH may not be pharmacologically active. Additionally, *l*-MPH might contribute to the behavioral and side-effect profiles of *d,l*-MPH during the treatment of ADHD ([@b9-ndt-2-467]).

Immediate-release and extended-release form of d-MPH
====================================================

The immediate-release (IR) *d*-MPH product is deemed to provide effective management of ADHD at half the dose of racemic MPH products and was shown to be effective and well tolerated in clinical trials ([@b45-ndt-2-467]; [@b2-ndt-2-467]; [@b36-ndt-2-467]; [@b60-ndt-2-467]). An initial pharmacokinetic study showed that after an oral dose of *d*-MPH, plasma *d*-MPH concentration increased rapidly, reaching maximum levels at 1--1.5 hours post-dose in fasting states. Plasma pharmacokinetics of *d*-MPH were similar to *d,l*-MPH given the equimolar amounts of *d*-MPH. The mean plasma elimination half-life for *d*-MPH is approximately 2.2 hours ([@b1-ndt-2-467]). However, recent studies, including one post hoc analysis ([@b59-ndt-2-467]), one open-labeled ([@b38-ndt-2-467]), and three placebo-controlled clinical studies ([@b2-ndt-2-467]; [@b36-ndt-2-467]; [@b60-ndt-2-467]) in children with ADHD, suggested that IR *d*-MPH may produce a longer duration of therapeutic action (≥ 6 hours) which cannot be explained solely on the basis of the agent's pharmacokinetics.

Some authors have postulated that the need for a midday dose for IR MPH products may erode social functioning and sometimes the self-esteem of children with ADHD. Thus, an extended-release form of *d*-MPH (*d-*MPH-XR) was designed, known as Focalin XR^®^, and approved by FDA for clinical use in May 2005. This product is a modified release capsule formulation of *d*-MPH specifically engineered to deliver a bimodal (biphasic) release of *d*-MPH that mimics a twice daily *d*-MPH dosing (ie, two distinct peaks approximately 4 hours apart). The *d-*MPH-XR product uses the same proprietary SODAS (Spheroidal Oral Drug Absorption System) technology as one of the racemic MPH products (Ritalin-LA^®^) currently on the market. For each of these products, capsules are filled with a mixture of 50% immediate-release beads and 50% enteric-coated, delayed-release beads, thus providing immediate release and a second delayed-release component. After administration of *d-*MPH-XR, the first peak concentration (C~max1~) of *d-*MPH occurs on average after 1.5 hours (typical range 1--4 hours). The mean time to the inter-peak minimum is slightly shorter, and time to the second peak (t~max2~) is slightly longer for *d*-MPH- XR given once daily (about 6.5 hours, range 4.5--7 hours) compared with the IR *d*-MPH given in two doses 4 hours apart. The *d*-MPH-XR product given once daily exhibits a lower second peak concentration (C~max2~), higher inter-peak minimum concentrations, and fewer peak and trough fluctuations than the IR form of the agent, given in two doses 4 hours apart. The area under the plasma concentration-time curve (AUC) after administration of *d-*MPH-XR given once daily is equivalent to the same total dose of IR *d-*MPH tablets given in two doses 4 hours apart ([@b34-ndt-2-467]).

The clinical efficacy as well as safety of *d-*MPH-XR in treating children with ADHD was demonstrated in a randomized, double-blind, placebo-controlled clinical trial ([@b17-ndt-2-467]). In this study, flexible dosing schedules of between 5 and 30 mg of *d-*MPH-XR were administered once daily over a 7-week period. [@b17-ndt-2-467] reported that *d-*MPH-XR was associated with significantly improved attention and behavior in children with ADHD. [@b39-ndt-2-467], [@b40-ndt-2-467], in two separate studies, demonstrated that the therapeutic effect significantly differentiated from placebo during each time point of the 12-hour laboratory classroom studies. Both of these studies employed a double-blind, placebo-controlled, crossover design. The sample sizes were slightly more than 50 patients in each trial; all subjects satisfied DSM-IV criteria for ADHD. The children ranged in age between 6 and 12 years. In both studies, the *d*-MPH-XR dose administered was 20 mg/day. In the two studies, Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) scales and math tests were administered. Significant differences were observed across all measures and in each of the subscales at each of the time points studied. Another noteworthy observation is related to the elapsed time at which efficacy was first detected. In the [@b39-ndt-2-467] study significant differences were noted at the first time point measured, which was half an hour after medication administration.

Conclusions
===========

Based on the information we have reviewed it seems that *d*-MPH is a useful agent in the treatment of ADHD. Furthermore, it should be noted it is the only MPH product approved for the treatment of this disorder in adults. The literature reviewed identified that there are meaningful differences in the clinical efficacy and pharmacokinetic profile between the *d-* and *l-*isomers of MPH. When comparing the single isomer with the racemic compound, a consistently noted difference across studies is that *d-*MPH has a longer duration of action than *d,l*-MPH. This has been reported with both immediate-release and extended-release preparations. Further study is required to more fully understand the side-effect differences between the *d*-isomer and its racemic counterpart.
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